

**Common variants of the novel type 2 diabetes genes, *CDKAL1* and *HHEX/IDE*, are associated with decreased pancreatic  $\beta$ -cell function**

Laura Pascoe BSc.Hons.

Diabetes Research Group, Newcastle University, Newcastle upon Tyne, UK

Andrea Tura PhD

CNR Institute of Biomedical Engineering, Padova, Italy

Sheila K. Patel PhD

Cardiovascular Research Group, Department of Medicine, University of Melbourne, Australia

Ibrahim M. Ibrahim MB.BS

Diabetes Research Group, Newcastle University, Newcastle upon Tyne, UK

Ele Ferrannini PhD

University of Pisa, School of Medicine, Pisa, Italy

The RISC Consortium

Membership of the RISC Consortium is listed on supporting on line text

The UK Type 2 Diabetes Genetics Consortium

Membership of the UK Type 2 Diabetes Genetics Consortium is listed on supporting on line text

Eleftheria Zeggini PhD

Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, and Wellcome Trust Centre for Human Genetics University of Oxford, Oxford, UK

Michael N. Weedon PhD

Diabetes Genetics Group and Genetics of Complex traits, Peninsula Medical School, Exeter, UK

Andrea Mari PhD

CNR Institute of Biomedical Engineering, Padova, Italy

Andrew T. Hattersley DM

Diabetes Genetics Group and Genetics of Complex traits, Peninsula Medical School, Exeter, UK

Mark I. McCarthy MD

Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, and Wellcome Trust Centre for Human Genetics University of Oxford, Oxford, UK

Timothy M. Frayling PhD

Diabetes Genetics Group and Genetics of Complex traits, Peninsula Medical School, Exeter, UK

Mark Walker MD

Diabetes Research Group, Newcastle University, Newcastle upon Tyne, UK

**Running Title: *CDKAL1* and *HHEX* are associated with  $\beta$ -cell function**

**Corresponding author**

Professor Mark Walker

School of Clinical Medical Sciences, 4<sup>th</sup> Floor William Leech Building,

The Medical School, Newcastle University,

Framlington Place, Newcastle upon Tyne, NE2 4HH, UK

Email: Mark.Walker@ncl.ac.uk

Received for publication 9 May 2007 and accepted in revised form 24 August 2007.

Additional information for this article can be found in an online appendix at <http://diabetes.diabetesjournals.org>

## **Abstract**

**Objective:** type 2 diabetes is characterized by impaired pancreatic  $\beta$ -cell function and decreased insulin sensitivity. Genome wide association studies have identified common, novel type 2 diabetes susceptibility loci within the *FTO*, *CDKAL1*, *CDKN2A/CDKN2B*, *IGF2BP2*, *HHEX/IDE* and *SLC30A8* gene regions. Our objective was to explore the relationships between the diabetes associated alleles and measures of  $\beta$ -cell function and whole body insulin sensitivity.

**Research Design and Methods:** 1276 healthy subjects of European ancestry were studied at 19 centres. Indices of  $\beta$ -cell function (including 30min insulin response and glucose sensitivity) were derived from a 75g OGTT and whole body insulin sensitivity (M/I) was assessed by hyperinsulinemic-euglycemic clamp. Genotype/phenotype relationships were studied by linear trend analysis correcting for age, sex and recruitment centre.

**Results:** the *CDKAL1* and *HHEX/IDE* diabetes associated alleles were both associated with decreased 30min insulin response (both,  $p=0.0002$ ) and decreased pancreatic  $\beta$ -cell glucose sensitivity ( $p=9.86 \times 10^{-5}$  and 0.009, respectively), and these relationships remained after correction for M/I. The *FTO* susceptibility allele showed a weak but consistent association with increased adiposity, which in turn was linked to a decrease in M/I. However, none of the other novel diabetes susceptibility alleles were associated with insulin sensitivity.

**Conclusions:** the *CDKAL1* and *HHEX/IDE* diabetes associated alleles are associated with decreased pancreatic  $\beta$ -cell function, including decreased  $\beta$ -cell glucose sensitivity that relates insulin secretion to plasma glucose concentration. We confirmed the association between the *FTO* allele and increased adiposity, but none of the other novel susceptibility alleles was associated with whole body insulin sensitivity.

## Introduction

Type 2 diabetes is a complex trait characterized by decreased insulin secretion and decreased insulin action at target tissues. Knowledge of the molecular mechanisms and the underlying genetic architecture remain incomplete, although recent progress has been made through the genome-wide association (GWA) analyses (1-6). As well as confirming the involvement of *TCF7L2*, *PPARG* and *KCNJ11*, the GWAs have detected novel type 2 diabetes susceptibility loci within or close to the *FTO* (fat mass and obesity associated), *CDKAL1* (cyclin-dependent kinase 5 regulatory subunit associated protein 1-like 1), *CDKN2A/CDKN2B* (encoding the tumour suppressors p15<sup>INK4b</sup> and p16<sup>INK4a</sup>, respectively), *IGF2BP2* (IGF2 binding protein2), *HHEX/IDE* (homeobox, hematopoietically expressed/insulin degrading enzyme) and *SLC30A8* (zinc transporter) genes. With the exception of *FTO* that alters diabetes risk through increased adiposity (6), it is not known how variation within these genes increase diabetes susceptibility, although initial work suggests that *CDKAL1* and *SLC30A8* might act through altered pancreatic  $\beta$ -cell function (1-3).

The purpose of this study was to explore the relationship between the replicated susceptibility variants and detailed phenotypes of pancreatic  $\beta$ -cell function and whole body insulin sensitivity. To do this, we used the RISC (Relationship between Insulin Sensitivity and Cardiovascular Disease) cohort that comprises non-diabetic healthy European subjects recruited as part of a long-term study of insulin sensitivity and cardiovascular disease (7). A major benefit of using this healthy, disease-free cohort is that it avoids the secondary metabolic effects of the established diabetic state that can confound and obscure the relationship between the gene variants and indices of pancreatic  $\beta$ -cell function and insulin action.

## Methods

Table 1 summarizes the key phenotypic data for the men and women, confirming that this was a cohort of healthy subjects. The study recruitment methods and inclusion/exclusion criteria have been previously described (7). Briefly, healthy men and women of European ancestry, aged between 30-60 years, were recruited from 19 centres in 14

European countries. Subjects with diabetes, hypertension or dyslipidemia were excluded (7). The analysis presented in this paper is based on 1276 subjects who had passed the eligibility criteria and had completed genotype data. Local ethics committee approval was obtained by each recruitment centre and written consent was obtained from all participants.

Subjects underwent detailed anthropometric assessment and 75g OGTT with blood sampling before and 30, 60, 90 and 120 min after the oral glucose load. Fat mass was determined as the difference between body weight and fat-free mass determined by bioimpedance (Tanita International Division, UK). On a separate day within one month of the OGTT, subjects underwent a hyperinsulinemic-euglycemic clamp as previously reported (7). To ensure consistency across study centres, the clamp procedure was standardised and each centre underwent pre-study training. Clamp data was then transferred and analysed at the RISC co-ordinating centre (Pisa, Italy), and quality assured against pre-set criteria. These were as follows: clamped glucose levels within 20% of target (fasting glucose concentration) and CV of  $\leq 15\%$ , and avoidance of hypoglycaemia (glucose  $< 3.5$  mmol/l). Insulin sensitivity was assessed as the mean glucose infusion rate over the last 40 min of the clamp, corrected for the mean plasma insulin levels achieved during the same period (M/I).

Pancreatic  $\beta$ -cell function was assessed using the OGTT data. The 30min insulin response (8) was calculated as the ratio of the insulin concentration increment to the 30min glucose concentration (30min Insulin - 0min insulin / 30min glucose). Indices of  $\beta$ -cell function parameters were derived from mathematical analysis of plasma glucose and C-peptide, using C-peptide deconvolution (9) and a model illustrated previously (10,11). In short, the model describes the relationship between glucose concentration and insulin secretion (ISR). It includes an ISR vs. plasma glucose concentration dose-response curve (modulated by a potentiation factor accounting for effects due to hyperglycemia exposure and incretins) and a parameter describing early insulin release (rate sensitivity, marker of first phase secretion). Key parameter is  $\beta$ -cell glucose sensitivity, i.e. the slope of dose-response curve. An

OGTT derived measure of insulin sensitivity (OGIS) was also calculated as previously described (12)

Samples were processed and stored locally prior to transfer to the central assay laboratories and analysed as previously reported (7). Genomic DNA was extracted using a Nucleon BACC2 kit (Tepnel Life Sciences Plc, Manchester, UK). SNPs were selected as those best representing the recently reported type 2 diabetes associations and for which there were robust assays. All SNPs were genotyped by KBiosciences (3,6), except the Pro12Ala variant of *PPARG* which was genotyped by PCR-RFLP (13). A haplotype formed by the T alleles of rs10757283 and rs10811661 in the *CDKN2A/2B* region was associated with type 2 diabetes more strongly than the individual SNPs (3). We therefore used unphased software (14) to assess the association between this haplotype and the traits under investigation.

Variables with a positive skewed distribution (M/I, 30min insulin response, and all model parameters from the  $\beta$ -cell model) were log transformed to normalize distributions. These data are presented as the median [interquartile range].

As all of the novel type 2 diabetes risk alleles conformed to an additive inheritance pattern (3), linear trend analysis was first performed to test for associations between SNP genotypes and selected phenotypes after adjusting for age, sex and recruitment centre. If a SNP displayed a non-additive inheritance pattern for a given phenotype, General Linear Model (GLM) analysis was used to test for association. For all analyses,  $p \leq 0.01$  was considered statistically significant. We calculated that the cohort, for example, had 80% power at  $p=0.01$  to detect differences of 0.13 and 0.18 SDs per allele for minor allele frequencies of 0.44 and 0.30, respectively.

## Results

The genotype frequencies for the 8 SNPs and the Pro12Ala variant are summarised in the on-line Supplementary Table 1 (available at <http://diabetes.diabetesjournals.org>), and all were in Hardy-Weinberg equilibrium. Although all analyses were corrected for recruitment centre, we compared genotype frequencies between subjects from North and South European recruitment centres. There were small but significant differences

for rs564398, rs9939609 and rs1801282 (all  $p < 0.05$ ).

Table 2 summarizes the relationships between the diabetes associated alleles and the key phenotypic traits, namely whole body insulin sensitivity (M/I) and two indices of  $\beta$ -cell function (30min insulin response and  $\beta$ -cell glucose sensitivity). The key findings are that the diabetes risk alleles for SNPs rs10946398 and rs1111875 of the *CDKAL1* and *HHEX/IDE* gene regions, respectively, showed significant associations with the measures of  $\beta$ -cell function. For *CDKAL1*, the diabetes risk allele was associated with decreased glucose sensitivity ( $p=9.86 \times 10^{-5}$ ) and decreased 30min insulin response ( $p=0.0002$ ). These associations remained significant after adjustment for M/I ( $p=0.0005$  and  $p=0.006$ , respectively). For *HHEX/IDE*, the diabetes risk allele was associated with decreased 30min insulin response ( $p=0.0002$ ) and a trend for decreased glucose sensitivity ( $p=0.009$ ). Again, these associations remained after adjustment for M/I ( $p=0.0005$  and  $p=0.01$ , respectively). None of the other variants, including the *CDKN2A/2B* risk haplotype, showed an association with any measures of  $\beta$ -cell function.

We included the *PPARG* Pro12Ala variant as a "positive control", based upon previous reports of an association between this variant and insulin sensitivity (15,16). This observation was replicated by GLM analysis that showed a borderline significant association between the Ala allele and increased M/I ( $p=0.026$ ), which remained after correction for BMI ( $p=0.006$ ). In light of the previously reported relationship between *FTO* and BMI, we specifically examined the relationship between rs9939609 and three measures of adiposity (Table 2). There was an association between the diabetes susceptibility allele and increased adiposity, that was not strongly significant (BMI:  $p=0.022$ ), but was consistent with the effect sizes previously reported (6). We also found an association between the allele and decreased insulin sensitivity ( $p=0.023$ ), but this was no longer evident after correction for BMI. None of the other novel diabetes susceptibility alleles or the *CDKN2A/2B* risk haplotype showed a significant association with whole body insulin sensitivity. There were no significant associations between the OGTT derived measure of insulin sensitivity

and the diabetes susceptibility alleles (online Supplementary Table 2).

We assessed whether any of the SNPs showed evidence of interacting with BMI to influence 30min insulin response,  $\beta$ -cell glucose sensitivity and M/I by regression analysis adjusting for the usual covariates. There was no evidence of interactive effects (all  $p > 0.05$ ).

### Discussion

Recent GWAs have identified novel type 2 diabetes susceptibility loci within or close to the genes encoding *FTO*, *CDKAL1*, *CDKN2A/CDKN2B*, *IGF2BP2*, *HHEX/IDE* and *SLC30A8* (1-6). The purpose of this study was to examine the relationships between the diabetes associated alleles and measures of  $\beta$ -cell function and whole body insulin sensitivity.

Three key findings have emerged from this study. First, the type 2 diabetes associated alleles of the SNPs located within the *CDKAL1* and *HHEX/IDE* gene regions were associated with impaired  $\beta$ -cell function. Both these SNPs showed clear associations with increased type 2 diabetes risk in GWA studies of subjects of European ancestry, with ORs of 1.12 and 1.13 for *CDKAL1* and *HHEX/IDE*, respectively (3-5). For each gene, the type 2 diabetes susceptibility allele was associated with decreased 30min insulin response and decreased  $\beta$ -cell glucose sensitivity. These relationships remained after correction for whole body insulin sensitivity (M/I), in keeping with primary defects of  $\beta$ -cell function rather than secondary changes in response to altered insulin sensitivity. It is worth noting, however, that these are not direct measures of insulin secretion, but provide indirect indices of  $\beta$ -cell function. The measure of  $\beta$ -cell glucose sensitivity represents the mean slope of the dose-response relationship between insulin secretion determined from C-peptide kinetics and plasma glucose concentration. Decreased  $\beta$ -cell glucose sensitivity therefore indicates decreased insulin secretion over the glucose concentration range achieved during the OGTT. We recently investigated predictors of progression to abnormal glucose tolerance in a high-risk non-diabetic cohort, and found that decreased glucose sensitivity was the strongest independent predictor when all the other model parameters and the early insulin response were included (10). Our results

support those of Steinthorsdottir and colleagues who showed that variation within *CDKAL1* was similarly associated with type 2 diabetes and decreased early insulin response (2). As previously reported (2-5), the role of *CDKAL1* in pancreatic  $\beta$ -cell function remains unknown, although we found that it is strongly expressed in human adult pancreatic islets relative to other tissues (3).

The susceptibility allele at rs1111875 within the *HHEX/IDE* gene region was shown to be associated with type 2 diabetes in both our own and other GWA studies (1-5). *HHEX* is highly expressed in pancreatic islet tissue (3), and failure of ventral pancreas development is a feature of *HHEX* null mice (17). Conditional knock down of *HHEX* in pancreatic  $\beta$ -cells will help to define its role in  $\beta$ -cell differentiation and function. It is important to note, however, that the association signal is a region of extended LD that includes other genes, including *IDE* and *KIF11* that encode the insulin degrading enzyme and kinesin-interacting factor, respectively (3).

We have found no relationship between the indices of  $\beta$ -cell function and the susceptibility alleles in the other novel gene regions (*CDKN2A/CDKN2B*, *IGF2BP2* and *SLC30A8* genes). This is somewhat surprising, as some of the risk alleles had ORs close to those of *CDKAL1* and *HHEX/IDE* (3). Other possible explanations are that these genes do not impact upon the phenotypes that we have examined, or perhaps the effect of the risk alleles is strongly age dependent as our is a relatively young cohort (Table 1).

The second finding is that we confirmed that the *FTO* susceptibility allele is associated with increased adiposity, and this was consistent across all three measures of adiposity (BMI, WHR and fat mass). The *FTO* susceptibility allele was also weakly associated with decreased insulin sensitivity, but this was explained through the increased adiposity.

The third finding is that none of the other novel susceptibility alleles was associated with altered whole body insulin sensitivity. This is despite the fact that the RISC cohort is one of the largest collections of healthy subjects, all of European ancestry, to be assessed for whole body insulin sensitivity using the gold standard hyperinsulinemic-euglycemic clamp technique. We

acknowledge however that the exclusion criteria may have served to compress the distribution of insulin sensitivity across the cohort and limited the scope to detect associations between this phenotype and the diabetes susceptibility alleles. Nonetheless, we were able to show that homozygous Ala allele carriers of the *PPARG* Pro12Ala variant have greater whole body clamp derived insulin sensitivity compared to Pro allele carriers, in keeping with the findings of a similar study that assessed whole body insulin sensitivity by hyperinsulinemic-euglycemic clamp (16). This would suggest, therefore, that if any of the other novel diabetes susceptibility variants do influence insulin sensitivity, then their effects must be

*CDKAL1 and HHEX are associated with  $\beta$ -cell function*

comparatively weak and will require a larger cohort to be detected.

In conclusion, we have shown that the *CDKAL1* and *HHEX/IDE* susceptibility alleles are associated with decreased pancreatic  $\beta$ -cell function, and have confirmed the relationship between variation in *FTO* and increased adiposity. However, none of the other novel diabetes susceptibility alleles was associated with altered whole body insulin sensitivity.

#### **Acknowledgements**

The RISC Study is supported by European Union grant QL1-CT-2001-01252 and AstraZeneca. Laura Pascoe is the recipient of a joint BBSRC and Unilever UK Ltd case PhD studentship

## References

1. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, Balkau B, Heude B, Charpentier G, Hudson TJ, Montpetit A, Pshezhetsky AV, Prentki M, Posner BI, Balding DJ, Meyre D, Polychronakos C, Froguel P: A genome-wide association study identifies novel risk loci for type 2 diabetes. *Nature* 445:881-885, 2007
2. Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T, Walters GB, Styrkarsdottir U, Gretarsdottir S, Emilsson V, Ghosh S, Baker A, Snorraddottir S, Biarnason H, Ng MCY, Hansen T, Bagger Y, Wilensky RL, Reilly MP, Adeyemo A, Chen Y, Zhou J, Gudnason V, Chen G, Huang H, Lashley K, Doumatey A, So WY, Ma RCY, Andersen G, Borch-Johnsen K, Jorgensen T, Vliet-Ostaptchouk JV, Hofker MH, Wijmenga C, Christiansen C, Rader DJ, Rotimi C, Gurney M, Chan JCN, Pedersen O, Sigurdsson C, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K: A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. *Nature Genetics* 39:770-775, 2007
3. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, Timpson NJ, Perry JRB, Rayner NW, Freathy RM, Barrett JC, Shields B, Morris AP, Ellard S, Groves CJ, Harries LW, Marchini JL, Owen KR, Knight B, Cardon LR, Walker M, Hitman GA, Morris AD, Doney ASF, The Wellcome Trust Case Control Consortium, McCarthy MI, Hattersley AT: Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. *Science* 316:1336-1341, 2007
4. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu T, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, Hetrick KN, Barnhart MW, Bark CW, Goldstein JL, Watkins L, Xiang F, Saramies J, Buchanan TA, Watanabe RM, Valle TT, Kinnunen L, Abecasis GR, Pugh EW, Doheny KF, Bergman RN, Tuomilehto J, Collins FS, Boehnke M: A genome-wide association study of Type 2 diabetes in Finns detects multiple susceptibility variants. *Science* 316:1341-1345, 2007
5. Diabetes Research Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes for Biomedical Research: Genome-wide association analysis identifies loci for Type 2 diabetes and triglyceride levels. *Science* 316:1331-1336, 2007
6. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JRB, Elliott KS, Lango H, Rayner NW, Shields B, Harries LW, Barrett JC, Ellard S, Groves CJ, Knight B, Patch AM, Ness AR, Ebrahim S, Lawlor DA, Ring SM, Ben-Shlomo Y, Jarvelin MR, Sovio U, Bennett AJ, Melzer D, Ferrucci L, Loos RJJ, Barroso I, Wareham NJ, Karpe F, Owen KR, Cardon LR, Walker M, Hitman GA, Palmer CAN, Doney ASF, Morris AD, Davey-Smith G, The Wellcome Trust Case Control Consortium, Hattersley AT, McCarthy MI: A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. *Science* 316:889-894, 2007
7. Hills SA, Balkau B, Coppock SW, Dekker JM, Mari A, Natali A, Walker M, Ferrannini E: The EGIR-RISC study (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): 1. Methodology and Objectives. *Diabetologia* 47:566-570, 2004.
8. Wareham NJ, Phillips DI, Byrne CD, Hales CN: The 30 minute insuline incremental response in an oral glucose tolerance test as a measure of insulin secretion. *Diabetic Medicine*. 12: 931, 1995.
9. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. *Diabetes* 41:368-377, 1992.
10. Walker M, Mari A, Jayapaul MK, Bennett SMA, Ferrannini E: Impaired  $\beta$  cell glucose sensitivity and whole-body insulin sensitivity as predictors of hyperglycaemia in non-diabetic subjects. *Diabetologia* 48: 2470-2476, 2005.
11. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E: Meal and oral glucose tests for assessment of  $\beta$ -cell function: modeling analysis in normal subjects. *Am J Physiol Endocrinol Metab* 283: E1159-E1166, 2002.
12. Mari A, Pacini G, Murphy E, Kudvik B, Nolan JJ: A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. *Diabetes Care* 24: 539-548, 2001
13. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnell DP, Burns DK, Roth J, Shuldiner AR: Molecular scanning of the human peroxisome proliferator activated receptor  $\gamma$

- (hPPAR $\gamma$ ) gene in diabetic caucasians: identification of a Pro12Ala PPAR $\gamma$ 2 missense mutation. *Biochem Biophys Res Commun* 241: 270-274, 1997
14. Dudbridge F: Pedigree disequilibrium tests for multilocus haplotypes. *Genetic Epidemiology* 25: 115-121, 2003
  15. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J: A Pro12Ala substitution in PPAR $\gamma$ 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. *Nature Genetics* 20: 284-7, 1998.
  16. Ek J, Andersen G, Urhammer SA, Hansen L, Carstensen B, Borch-Johnsen K, Drivsholm T, Berglund L, Hansen T, Lithell H, Pedersen O: Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor- $\gamma$ 2 (PPAR- $\gamma$ 2) gene in relation to insulin sensitivity among glucose tolerant Caucasians. *Diabetologia* 44: 1170-1176, 2001.
  17. Bort R, Martinez-Barbera JP, Beddington RSP, Zaret KS: Hex homeobox gene-dependent tissue positioning is required for organogenesis of the ventral pancreas. *Development* 131, 797-806, 2004

Table 1: Key characteristics for males and females in the RISC cohort.

	Male	Female
N	575	701
Age (years)	43 [8]	44 [8]
BMI (kg/m <sup>2</sup> )	26.4 [3.5]	24.9 [4.3]
Fat Mass (kg)	19.0 [8.1]	22.7 [9.2]
Fat Free Mass (kg)	64.9 [7.1]	44.9 [4.4]
Waist-Hip Ratio	0.92 [0.08]	0.82 [0.09]
Fasting blood glucose (mmol/l)	5.2 [0.5]	4.9 [0.6]
Impaired Glucose Tolerance (%)	4	5
Triglycerides (mmol/l)	1.1 [1.7]	0.9 [1.6]
Cholesterol (mmol/l)	4.9 [0.9]	4.8 [0.9]
High Density Lipoprotein (mmol/l)	1.2 [0.3]	1.6 [0.4]
Systolic B.P. (mmHg)	122.2 [10.8]	113.7 [12.6]
Diastolic B.P. (mmHg)	76.5 [7.6]	72.8 [8.1]
M/I ( $\mu\text{mol min}^{-1} \text{kg}_{\text{ffm}}^{-1} \text{nM}^{-1}$ )*	109 [79-151]	138 [105-187]
30min Insulin Response (pmol/mmol)*	26.5 [17.7-39.8]	26.3 [18.6-79.4]
$\beta$ -cell glucose sensitivity ( $\text{pmol min}^{-1} \text{m}^{-2} \text{mM}^{-1}$ )*	101 [74-139]	119 [82-175]

Data presented as mean [SD] or \*Geometric mean [25th – 75th quartile]

Table 2: Relationships between diabetes susceptibility alleles and measures of beta-cell function (30min Insulin Response and beta-cell glucose sensitivity) and whole body insulin sensitivity (M/I). Risk allele/variant in bold.

Genomic region/ variant	Genotype 1/2	Trait	11	12	22	p
rs10757283 <i>CDKN2B</i>	C/T	30min Ins Resp	25.7 (17.8-37.2)	26.3 (18.6-38.9)	26.3 (16.6-38.9)	0.678
		Glucose Sens	111 (78-156)	114 (80-158)	114 (76-160)	0.336
		M/I	133 (93-186)	127 (91-176)	124 (86-170)	0.077
rs10811661 <i>CDKN2B</i>	T/C	30min Ins Resp	25.7 (17.4-37.8)	28.2 (20.0-38.9)	28.8 (15.8-38.9)	0.216
		Glucose Sens	115 (79-157)	109 (78-164)	120 (78-157)	0.504
		M/I	130 (94-179)	123 (89-173)	146 (101-181)	0.293
rs564398 <i>CDKN2B</i>	A/G	30min Ins Resp	26.3 (17.4-38.9)	26.9 (18.6-38.0)	25.1 (17.0-36.3)	0.367
		Glucose Sens	113 (77-149)	114 (79-169)	107 (71-147)	0.413
		M/I	123 (91-173)	129 (92-176)	134 (92-189)	0.065
rs10946398 <i>CDKAL1</i>	A/C	30min Ins Resp	28.2 (19.5-39.8)	25.1 (17.4-36.3)	24.5 (15.8-36.3)	<b>0.0002</b>
		Glucose Sens	119 (83-170)	111 (77-155)	102 (68-140)	<b>9.86 X10<sup>-5</sup></b>
		M/I	126 (86-172)	129 (95-180)	117 (89-178)	0.108
rs1111875 <i>HHEX/IDE</i>	G/A	30min Ins Resp	25.1 (17.0-35.5)	26.0 (18.2-39.8)	29.5 (20.0-39.8)	<b>0.0002</b>
		Glucose Sens	107 (72-154)	117 (81-156)	120 (82-175)	<b>0.009</b>
		M/I	127 (91-175)	128 (91-176)	132 (95-184)	0.135
rs13266634 <i>SLC30A8</i>	C/T	30min Ins Resp	25.7 (17.4-37.5)	27.0 (19.5-38.9)	25.7 (18.4-38.9)	0.128
		Glucose Sens	112 (76-155)	114 (80-159)	125 (92-186)	0.072
		M/I	128 (92-179)	126 (89-167)	153 (96-196)	0.330
rs4402960 <i>IGF2BP2</i>	G/T	30min Ins Resp	26.9 (17.8-38.0)	25.1 (18.2-38.0)	28.5 (20.8-39.1)	0.540
		Glucose Sens	115 (80-162)	111 (76-154)	118 (80-158)	0.067
		M/I	131 (92-177)	126 (91-176)	126 (87-160)	0.204
rs9939609 <i>FTO</i>	A/T	30min Ins Resp	25.1(18.0-37.2)	26.6 (17.5-38.9)	26.3 (19.1-38.0)	0.690
		Glucose Sens	111 (72-147)	113 (79-158)	114 (81-159)	0.312
		M/I	123 (89-167)	127 (88-177)	134 (100-182)	0.023
		BMI	25.5 (23.4-28.4)	25.1 (22.8-28.1)	24.6 (22.4-27.4)	0.022
		WHR	0.88 (0.80- 0.94)	0.86 (0.79-0.93)	0.85 (0.78-0.92)	<b>0.009</b>
		Fat Mass	21.3 (14.2-27.9)	19.7 (14.7-25.6)	19.3 (14.4-24.6)	0.035
Pro12Ala (rs1801282) <i>PPARG</i>	Pro/Ala	30min Ins Resp	22.4 (18.6-28.2)	24.5 (16.6-34.7)	26.9 (18.6-39.8)	0.028
		Glucose Sens	136 (80-164)	107 (75-149)	115 (79-160)	0.612
		M/I	127 (93-176)	125 (87-179)	168 (134-210)	0.212

Data presented as median (interquartile range, 25th – 75th quartile). P values for linear trend analysis adjusted for age, sex and recruitment centre. Abbreviations and units as follows: 30min Ins Resp= 30min Insulin Response (pmol/mmol); Glucose Sens= Glucose Sensitivity (pmol min<sup>-1</sup> m<sup>-2</sup> mM<sup>-1</sup>); M/I= Whole body insulin sensitivity (μmol min<sup>-1</sup> kg<sub>fm</sub><sup>-1</sup> nM<sup>-1</sup>); BMI (kg/m<sup>2</sup>); Fat Mass (kg).